Arcus Biosciences Inc. (RCUS)
NYSE: RCUS
· Real-Time Price · USD
14.84
-0.21 (-1.40%)
At close: Oct 09, 2025, 10:56 AM
-1.40% (1D)
| Bid | 14.79 |
| Market Cap | 1.58B |
| Revenue (ttm) | 262M |
| Net Income (ttm) | -306M |
| EPS (ttm) | -3.14 |
| PE Ratio (ttm) | -4.73 |
| Forward PE | -3.33 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 14.88 |
| Volume | 143,232 |
| Avg. Volume (20D) | 826,473 |
| Open | 15.16 |
| Previous Close | 15.05 |
| Day's Range | 14.82 - 15.27 |
| 52-Week Range | 6.50 - 18.98 |
| Beta | 0.77 |
| Ex-Dividend Date | n/a |
About RCUS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RCUS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RCUS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsArcus Biosciences Inc. is scheduled to release its earnings on
Nov 5, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 days ago
+8.46%
Arcus Biosciences shares are trading higher after ...
Unlock content with
Pro Subscription
5 months ago
-1.35%
Arcus Biosciences shares are trading lower after the company reported worse-than-expected Q1 sales results. Also, Wells Fargo lowered its price target on the stock from $29 to $26.
2 days ago · seekingalpha.com
Arcus Biosciences, Inc. (RCUS) Shareholder/Analyst Call TranscriptArcus Biosciences, Inc. (NYSE:RCUS ) Shareholder/Analyst Call October 6, 2025 10:00 AM EDT Company Participants Pia Eaves - Vice President of Investor Relations & Strategy Terry Rosen - Co-Founder, Ch...
1 month ago · businesswire.com
Arcus Biosciences to Participate in Three Upcoming Investor ConferencesHAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient...
